TCGA-BB-A6UO-01A-12R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.061187215
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.570
- MYC_TARGETS_V2+0.560
- MYC_TARGETS_V1+0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- ANGIOGENESIS+0.370
- INTERFERON_ALPHA_RESPONSE+0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- TNFA_SIGNALING_VIA_NFKB+0.310
- HYPOXIA+0.290
- INTERFERON_GAMMA_RESPONSE+0.280
Top 10 suppressed
- TGF_BETA_SIGNALING-0.330
- BILE_ACID_METABOLISM-0.280
- WNT_BETA_CATENIN_SIGNALING-0.260
- MITOTIC_SPINDLE-0.210
- HEME_METABOLISM-0.200
- APICAL_SURFACE-0.180
- SPERMATOGENESIS-0.150
- KRAS_SIGNALING_DN-0.140
- UV_RESPONSE_DN-0.130
- PI3K_AKT_MTOR_SIGNALING-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d9780581-dfca-4e83-9bb4-4836f22d910e | — | — | 0.829 |
| 2 | AUR-AER6-TTM7-A-1-1-R-A742-41 | — | C | 0.757 |
| 3 | TCGA-A2-A0SV-01A-11R-A084-07 | — | C | 0.753 |
| 4 | MDT-AP-1185 | Med | Medulloblastoma | 0.749 |
| 5 | 152AC0F4-B49F-49AE-BF76-45C70CA3FF7F | — | — | 0.742 |
| 6 | E7BE221B-273D-4C04-BE79-366E6455EFBC | — | — | 0.741 |
| 7 | TCGA-MT-A67D-01A-31R-A30B-07 | — | — | 0.736 |
| 8 | MDT-AP-1381 | Med | Medulloblastoma | 0.731 |
| 9 | DB8DD33B-34B6-4F4B-AD87-D666899A26BC | — | — | 0.725 |
| 10 | 4F09B010-97EC-4792-BF5A-42E9EF55894D | — | — | 0.722 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.570 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |